C. R. Bradley

2.0k total citations · 1 hit paper
39 papers, 1.5k citations indexed

About

C. R. Bradley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Ceramics and Composites. According to data from OpenAlex, C. R. Bradley has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Ceramics and Composites. Recurrent topics in C. R. Bradley's work include PARP inhibition in cancer therapy (17 papers), Glass properties and applications (9 papers) and Cancer Treatment and Pharmacology (7 papers). C. R. Bradley is often cited by papers focused on PARP inhibition in cancer therapy (17 papers), Glass properties and applications (9 papers) and Cancer Treatment and Pharmacology (7 papers). C. R. Bradley collaborates with scholars based in United States, United Kingdom and France. C. R. Bradley's co-authors include John Pippen, Debra A. Patt, Barry M. Sherman, Joyce O’Shaughnessy, Cynthia Osborne, J.K. Bates, C. Rocha, Valeria Ossovskaya, B. Sherman and J. P. Bradley and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

C. R. Bradley

39 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

2011 616 citations Joyce O’Shaughnessy, Cynthia Osborne et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by C. R. Bradley

Since Specialization

Citations

This map shows the geographic impact of C. R. Bradley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. R. Bradley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. R. Bradley more than expected).

Fields of papers citing papers by C. R. Bradley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. R. Bradley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. R. Bradley. The network helps show where C. R. Bradley may publish in the future.

Co-authorship network of co-authors of C. R. Bradley

This figure shows the co-authorship network connecting the top 25 collaborators of C. R. Bradley. A scholar is included among the top collaborators of C. R. Bradley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. R. Bradley. C. R. Bradley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer breakdown → 2011 ·New England Journal of Medicine ·Joyce O’Shaughnessy, Cynthia Osborne, John Pippen, (unknown), Debra A. Patt, (unknown), (unknown), Barry M. Sherman, C. R. Bradley	616
2	TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). 2011 ·Journal of Clinical Oncology ·Carey K. Anders, Rachita Nanda, (unknown), Kim T. Blackwell, Catherine Van Poznak, (unknown), A. M. Storniolo, NU Lin, Vered Stearns, (unknown), Shannon Puhalla, J. Carpenter, Michelle Melisko, Allison M. Deal, Clifford A. Hudis, Eric P. Winer, Charles M. Perou, C. R. Bradley, Antonio C. Wolff, LA Carey	3
3	P3-14-08: A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. 2011 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Patrick Flaherty, (unknown), Irene Wapnir, Bruce L. Daniel, (unknown), (unknown), (unknown), Elizabeth Schackmann, C. Rocha, B. Sherman, Anne Blackwood‐Chirchir, C. R. Bradley, (unknown)	2
4	Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. 2010 ·Journal of Clinical Oncology ·(unknown), X. Ye, Stuart A. Grossman, T. Mikkelsen, Myrna R. Rosenfeld, C. R. Bradley, April F. Eichler, Burt Nabors, Serena Desideri, Jeffrey G. Supko	10
5	Abstract P6-15-01: A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC) 2010 ·Cancer Research ·Stacey Moulder, Monica Mita, C. R. Bradley, C. Rocha, (unknown)	9
6	Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer 2009 ·Cancer Research ·Valeria Ossovskaya, Lingyun Li, Eugenia V. Broude, Chang‐Uk Lim, Igor B. Roninson, C. R. Bradley, Barry M. Sherman	13
7	Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. 2009 ·Cancer Research ·Joyce O’Shaughnessy, (unknown), (unknown), JL Blum, C. Rocha, Valeria Ossovskaya, B. Sherman, C. R. Bradley	11
8	G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial 2009 ·European Journal of Cancer Supplements ·Joyce O’Shaughnessy, Cynthia R. Osborne, John Pippen, (unknown), Debra A. Patt, (unknown), C. Rocha, Valeria Ossovskaya, B. Sherman, C. R. Bradley	9
9	Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial 2009 ·Journal of Clinical Oncology ·Joyce O’Shaughnessy, (unknown), John Pippen, (unknown), Debra A. Patt, (unknown), C. Rocha, Valeria Ossovskaya, B. Sherman, C. R. Bradley	34
10	Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial 2009 ·Journal of Clinical Oncology ·Joyce O’Shaughnessy, (unknown), John Pippen, (unknown), Debra A. Patt, (unknown), C. Rocha, Valeria Ossovskaya, B. Sherman, C. R. Bradley	73
11	First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors 2008 ·Journal of Clinical Oncology ·Scott Kopetz, Monica Mita, (unknown), Kamalesh K. Sankhala, J. M. Moseley, Barry M. Sherman, C. R. Bradley, A. W. Tolcher	54
12	Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer 2003 ·British Journal of Cancer ·Michael Braun, F. Adab, C. R. Bradley, Karen McAdam, (unknown), Nick Wadd, D. Rea, (unknown), Chris Twelves, (unknown), (unknown), Mark Saunders, (unknown), H. Anderson, A. McDonald, Jill Stewart, A. Robinson, (unknown), (unknown), Michel Seymour	13
13	The long-term alteration of borosilicate waste glasses 1993 ·University of North Texas Digital Library (University of North Texas) ·W.L. Ebert, J.K. Bates, C. R. Bradley, Edgar C. Buck, (unknown), N. R. Brown	1
14	Effects of Radiation Exposure on SRL 131 Composition Glass in a Steam Environment 1993 ·MRS Proceedings ·David J. Wronkiewicz, C. R. Bradley, J.K. Bates, L. M. Wang	7
15	Does Fully Radioactive Glass Behave Differently than Simulated Waste Glass? 1992 ·MRS Proceedings ·Xiaming Feng, J.K. Bates, C. R. Bradley, Edgar C. Buck	4
16	Alteration of tektite to form weathering products 1992 ·Nature ·J.J. Mazer, J.K. Bates, J. P. Bradley, C. R. Bradley, Christopher M. Stevenson	27
17	Accelerated Glass Reaction Under PCT Conditions 1992 ·MRS Proceedings ·W.L. Ebert, J.K. Bates, Edgar C. Buck, C. R. Bradley	16
18	Colloid Formation During Waste Form Reaction: Implications for Nuclear Waste Disposal 1992 ·Science ·J.K. Bates, J. P. Bradley, (unknown), C. R. Bradley, (unknown)	106
19	Water diffusion in tektites: An example of the use of natural analogues in evaluating the long-term reaction of glass with water 1992 ·Journal of Nuclear Materials ·J.J. Mazer, J.K. Bates, C. R. Bradley, Christopher M. Stevenson	8
20	Outward Transcutaneous Chemical Migration: Implications for Diagnostics and Dosimetry 1988 ·Skin Pharmacology and Physiology ·Carl C. Peck, Dale P. Conner, (unknown), Ramona G. Almirez, (unknown), Leroy D. Mell, Gail Murphy, (unknown), Laura M. Rowland, ‪David Ezra‬‏, (unknown), C. R. Bradley, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact